BRPI0810094A2 - Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas - Google Patents

Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas

Info

Publication number
BRPI0810094A2
BRPI0810094A2 BRPI0810094-2A2A BRPI0810094A BRPI0810094A2 BR PI0810094 A2 BRPI0810094 A2 BR PI0810094A2 BR PI0810094 A BRPI0810094 A BR PI0810094A BR PI0810094 A2 BRPI0810094 A2 BR PI0810094A2
Authority
BR
Brazil
Prior art keywords
diseases
treatment
kinase inhibitors
inhibitors useful
myeloproliferative
Prior art date
Application number
BRPI0810094-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel L Flynn
Peter A Petillo
Michael D Kaufman
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of BRPI0810094A2 publication Critical patent/BRPI0810094A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0810094-2A2A 2007-04-20 2008-04-18 Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas BRPI0810094A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91321607P 2007-04-20 2007-04-20
PCT/US2008/060833 WO2008131227A1 (en) 2007-04-20 2008-04-18 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases

Publications (1)

Publication Number Publication Date
BRPI0810094A2 true BRPI0810094A2 (pt) 2014-10-21

Family

ID=39872877

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0810094-2A2A BRPI0810094A2 (pt) 2007-04-20 2008-04-18 Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
BRPI0807717-7A2A BRPI0807717A2 (pt) 2007-04-20 2008-04-18 Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0807717-7A2A BRPI0807717A2 (pt) 2007-04-20 2008-04-18 Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.

Country Status (14)

Country Link
US (4) US20080269267A1 (enExample)
EP (5) EP2148677A4 (enExample)
JP (2) JP2010524970A (enExample)
KR (2) KR20100014811A (enExample)
CN (2) CN101878031A (enExample)
AU (4) AU2008251723A1 (enExample)
BR (2) BRPI0810094A2 (enExample)
CA (4) CA2684949A1 (enExample)
EA (1) EA200970700A1 (enExample)
IL (1) IL201650A0 (enExample)
MX (2) MX2009009066A (enExample)
RU (1) RU2009142851A (enExample)
SG (1) SG183054A1 (enExample)
WO (4) WO2008131253A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269267A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
JP5868855B2 (ja) * 2009-09-03 2016-02-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ チロシンキナーゼ調節剤としての化合物
WO2011062955A2 (en) * 2009-11-18 2011-05-26 University Of Massachusetts Compounds for modulating tlr2
WO2011069951A1 (en) 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
KR20130091331A (ko) * 2010-07-16 2013-08-16 교와 핫꼬 기린 가부시키가이샤 함질소 방향족 복소환 유도체
US20130165475A1 (en) * 2010-09-01 2013-06-27 Ascepion Pharmaceuticals, Inc. Deuterium-enriched heterocyclic compounds as kinase inhibitors
CN102408408A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物
CN102432592A (zh) * 2010-09-29 2012-05-02 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物及其制备方法
WO2012078673A1 (en) * 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
CN102558144A (zh) * 2010-12-22 2012-07-11 北大方正集团有限公司 一种芳基脲衍生物
CN102532113B (zh) * 2010-12-22 2014-09-10 北大方正集团有限公司 芳基脲衍生物
KR20120100027A (ko) * 2011-03-02 2012-09-12 한국생명공학연구원 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물
HRP20161786T1 (hr) 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
BR112014028991A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd triazóis como inibidores de kv3
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2879431A1 (en) * 2012-07-17 2014-01-23 Washington University Anti-mucus drugs and uses therefor
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA117573C2 (uk) 2012-11-13 2018-08-27 Ерей Біофарма Інк. Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CA2901332A1 (en) 2013-02-19 2014-08-28 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
ES2731773T3 (es) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
ITMI20132201A1 (it) * 2013-12-23 2015-06-24 Isagro Spa Processo per la sintesi regioselettiva di pirazoli
CN106866623A (zh) * 2014-04-08 2017-06-20 北大方正集团有限公司 多取代的吡啶化合物、制备方法、用途及药物组合物
CN109970614B (zh) 2014-05-15 2023-01-13 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
JP6900400B2 (ja) * 2016-02-02 2021-07-07 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ ピラゾールを調製する接触水素化方法
CN105646448B (zh) * 2016-02-03 2019-03-01 沈阳药科大学 吡啶类化合物及其用途
CN108341813B (zh) * 2017-01-24 2020-11-17 四川大学 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
CN111936484A (zh) * 2017-12-22 2020-11-13 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3124112A1 (en) 2018-12-28 2020-07-02 Deciphera Pharmaceuticals, Llc Csf1r inhibitors for use in treating cancer
US20220127335A1 (en) * 2019-03-06 2022-04-28 University Of Maryland, Baltimore Tetrameric protein scaffolds as nano-carriers of therapeutic peptides for treating cancer and other diseases
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PT3966206T (pt) 2019-05-10 2023-11-10 Deciphera Pharmaceuticals Llc Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos
JP7626722B2 (ja) 2019-06-17 2025-02-04 デシフェラ・ファーマシューティカルズ，エルエルシー アミノピリミジンアミドオートファジー阻害剤およびその使用方法
CA3140017A1 (en) 2019-07-19 2021-01-28 Aurore HICK Polyaromatic urea derivatives and their use in the treatment of muscle diseases
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
KR20230022457A (ko) * 2020-05-08 2023-02-15 조지아뮨 엘엘씨 Akt3 조절제
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
CN112830936B (zh) * 2021-01-08 2022-01-28 广西师范大学 核黄素化合物、其制备方法及应用
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
CN115772167B (zh) * 2021-09-08 2025-07-29 暨南大学 含脲结构的化合物及其应用
TW202337455A (zh) 2021-12-09 2023-10-01 美商迪賽孚爾製藥有限公司 Ｒａｆ激酶抑制劑及其使用方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2025122952A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1115350B (de) 1959-04-17 1961-10-19 Siemens Ag Selbstschalter, insbesondere Leitungsschutz-schalter, mit einem aus einem Kniegelenk bestehenden Antriebsmechanismus fuer das Schaltorgan
GB971307A (en) 1961-03-02 1964-09-30 Wellcome Found 5-anilinopyrimidines
GB1127875A (en) 1967-03-23 1968-09-18 Parke Davis & Co 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils
US3949002A (en) 1970-11-13 1976-04-06 Imperial Chemical Industries Limited Process for producing sulfone containing thiophenols
US3818024A (en) 1972-02-16 1974-06-18 Velsicol Chemical Corp Benzothiazol substituted thiadiazolidines
CH565887A5 (enExample) 1972-08-22 1975-08-29 Ciba Geigy Ag
US3939122A (en) * 1973-04-11 1976-02-17 Bayer Aktiengesellschaft Process for the preparation of compounds which contain hydantoin rings
FR2337554A1 (fr) 1976-01-08 1977-08-05 Buzas Andre Nouveaux derives de la pyrazolidinedione
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
FR2396549A2 (fr) 1977-07-06 1979-02-02 Buzas Andre Nouveaux derives de la pyrazolidinedione
US4256758A (en) 1979-06-11 1981-03-17 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4298743A (en) 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4296237A (en) * 1979-09-11 1981-10-20 Merck & Co., Inc. 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4432992A (en) * 1979-11-05 1984-02-21 Merck & Co., Inc. 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4366189A (en) 1979-12-21 1982-12-28 Ciba-Geigy Corporation 4-Heterocyclyl-4'-vinylstilbenes
JPS5915247A (ja) 1982-07-16 1984-01-26 Mitsubishi Paper Mills Ltd 画像形成方法
JPS59177557A (ja) * 1983-03-28 1984-10-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US4816454A (en) * 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
AU606808B2 (en) 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5254715A (en) 1990-11-07 1993-10-19 Warner-Lambert Company Aminosulfonyl carbamates
ES2106855T3 (es) * 1991-01-21 1997-11-16 Shionogi & Co Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
DE4302702A1 (de) 1993-02-01 1994-08-04 Bayer Ag Arylaminosulfonylharnstoffe
WO1994021617A1 (en) 1993-03-19 1994-09-29 Dowelanco A process for preparing halogenated isothiazoles
EP0692483A1 (en) 1993-03-30 1996-01-17 Yoshitomi Pharmaceutical Industries, Ltd. Cell adhesion inhibitor and thienotriazolodiazepine compound
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4337847A1 (de) 1993-11-05 1995-05-11 Bayer Ag Substituierte Phenylaminosulfonylharnstoffe
AU1108395A (en) 1993-12-07 1995-06-27 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
DE4343831A1 (de) 1993-12-22 1995-06-29 Magyar Tudomanyos Akademia Substituierte Sulfonylharnstoffe
FR2715155B1 (fr) 1994-01-19 1996-07-26 Mayoly Spindler Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation.
DE4414840A1 (de) 1994-04-28 1995-11-02 Bayer Ag Substituierte Phenylaminosulfonylharnstoffe
DK1221440T3 (da) 1994-06-15 2007-09-17 Otsuka Pharma Co Ltd Benzoheterocykliske derivater der er nyttige som vasopressin- eller oxytocinmodulatorer
ES2193205T3 (es) 1994-11-24 2003-11-01 Basilea Pharmaceutica Ag Nuevas bencil pirimidinas.
US5494925A (en) 1994-12-02 1996-02-27 Sterling Winthrop Inc. 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
WO1996019477A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Plc Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists
EP0739884B1 (en) 1995-04-24 2003-08-13 Semiconductor Energy Laboratory Co., Ltd. Liquid crystal compound and liquid crystal composition containing the same
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
GB9605945D0 (en) 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
AU723730B2 (en) * 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
JPH107804A (ja) 1996-06-25 1998-01-13 Japan Synthetic Rubber Co Ltd 熱硬化性樹脂組成物
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ATE230742T1 (de) 1997-03-27 2003-01-15 Great Lakes Chemical Europ 2-(2'-hydroxphenyl)-benzotriazole und ihre verwendung als lichtschutzmittel für organische polymere
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
US6235786B1 (en) * 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
ES2188005T3 (es) 1997-09-23 2003-06-16 Astrazeneca Ab Derivados de amidas para el tratamiento de enfermedades mediadas por citoquinas.
IT1295933B1 (it) 1997-10-30 1999-05-28 Great Lakes Chemical Italia 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
PL341356A1 (en) 1997-12-22 2001-04-09 Bayer Ag Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
AU739642B2 (en) 1997-12-22 2001-10-18 Bayer Healthcare Llc Inhibition of p38 kinase activity using substituted heterocyclic ureas
WO1999032110A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
CN100360507C (zh) * 1997-12-22 2008-01-09 拜尔有限公司 用取代杂环脲抑制raf激酶
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
EP0928790B1 (en) * 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
ATE234099T1 (de) 1998-04-24 2003-03-15 Leuven K U Res & Dev Immununterdrückende effekte von 8 substituierten xanthinderivaten
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2000275886A (ja) 1999-03-23 2000-10-06 Konica Corp 電子写真感光体、それを用いたプロセスカートリッジ及び画像形成装置
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6500628B1 (en) 2000-05-25 2002-12-31 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
CA2435446A1 (en) 2001-02-15 2002-08-29 Boehringer Ingelheim Pharmaceuticals, Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
JP4343534B2 (ja) * 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
AU2002241139B2 (en) 2001-03-23 2007-09-20 Merck Sharp & Dohme Limited Imidazo-pyrimidine derivatives as ligands for GABA receptors
EP1281399A3 (en) 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
EP1427412A1 (en) 2001-09-13 2004-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
EP1478358B1 (en) * 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
AU2003210969A1 (en) 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
CA2473634C (en) * 2002-02-25 2011-11-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
PE20040522A1 (es) * 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
EP1545523A1 (en) 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
US20040138216A1 (en) 2002-12-23 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
US20080045706A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
WO2004078128A2 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113352A1 (en) 2003-06-19 2004-12-29 Amedis Pharmaceuticals Ltd. Silylated heterocyclylurea derivatives as cytokine-inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US20090312349A1 (en) 2004-12-23 2009-12-17 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
EP1835934A4 (en) * 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080248487A1 (en) 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
US20080248548A1 (en) 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
US20080269267A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases

Also Published As

Publication number Publication date
EP2146717A1 (en) 2010-01-27
US20080261961A1 (en) 2008-10-23
MX2009009066A (es) 2009-09-02
US20080269254A1 (en) 2008-10-30
AU2008242720A1 (en) 2008-10-30
EP2146716A4 (en) 2010-08-11
US20080269267A1 (en) 2008-10-30
US8143293B2 (en) 2012-03-27
RU2009142851A (ru) 2011-05-27
EP2481736A1 (en) 2012-08-01
KR20100017184A (ko) 2010-02-16
CA2678639A1 (en) 2008-10-30
EP2146716A1 (en) 2010-01-27
EP2146717A4 (en) 2010-08-11
JP2010524970A (ja) 2010-07-22
MX2009011343A (es) 2009-11-05
IL201650A0 (en) 2010-05-31
KR20100014811A (ko) 2010-02-11
EP2146718A4 (en) 2010-08-11
CA2684949A1 (en) 2008-10-30
WO2008131253A1 (en) 2008-10-30
EP2148677A1 (en) 2010-02-03
US20080261965A1 (en) 2008-10-23
AU2008251723A1 (en) 2008-11-20
CA2684666A1 (en) 2008-11-20
EP2148677A4 (en) 2010-08-11
EP2146718A1 (en) 2010-01-27
WO2008131227A1 (en) 2008-10-30
CA2684950A1 (en) 2008-10-30
EA200970700A1 (ru) 2010-02-26
CN101801383A (zh) 2010-08-11
CN101878031A (zh) 2010-11-03
AU2008242767A1 (en) 2008-10-30
JP2010524974A (ja) 2010-07-22
WO2008140895A1 (en) 2008-11-20
WO2008131276A1 (en) 2008-10-30
AU2008242697A1 (en) 2008-10-30
BRPI0807717A2 (pt) 2014-05-20
SG183054A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
BRPI0810094A2 (pt) Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
BRPI0719195A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
BRPI0716981A2 (pt) Inibidores de cinase úteis para o tratamento de doenças proliferativas
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BR112012004970A2 (pt) inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
ATE453635T1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI0812293A2 (pt) Derivados de 2-oxo-3-benzilbenzoxazol-2 -ona e compostos relacionados como inibidores de met quinase para o tratamento de tumores
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
SI2349260T1 (sl) Inhibitorji janusovih kinaz za zdravljenje suhega očesa in drugih bolezni, povezanih z očmi
BRPI0918476A2 (pt) dímeros de pirrolobenzodiazepina assimétricos para o tratamento de doenças proliferativas
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0919004A2 (pt) composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
DE602007011906D1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]